Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B06 OTHER HEMATOLOGICAL AGENTS
B06A OTHER HEMATOLOGICAL AGENTS
B06AC Drugs used in hereditary angioedema
B06AC06 Berotralstat
D11674 Berotralstat hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Angioedema Agents
Kallikrein Inhibitors
Berotralstat
D11674 Berotralstat hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
44 Allergic agents
449 Miscellaneous
4490 Miscellaneous
D11674 Berotralstat hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG03079 Berotralstat
D11674 Berotralstat hydrochloride
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
DG03079 Berotralstat
D11674 Berotralstat hydrochloride
Transporter substrate
DG01665 ABCB1 substrate
DG03079 Berotralstat
D11674 Berotralstat hydrochloride
DG01913 ABCG2 substrate
DG03079 Berotralstat
D11674 Berotralstat hydrochloride
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Serine peptidases
KLKB1
D11674 Berotralstat hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11674
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11674
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11674
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11674
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11674
Drug transporters
D11674
Drug groups [BR:br08330]
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG03079 Berotralstat
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
DG03079 Berotralstat
Transporter substrate
DG01665 ABCB1 substrate
DG03079 Berotralstat
DG01913 ABCG2 substrate
DG03079 Berotralstat